Catalyst Event
Merck and Co Inc (MRK) · Other
From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)
4/28/2026, 12:00:00 AM
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
Korean Translation
미국 FDA가 HIV 치료 후보 약물인 도라비린/이슬라트라비르의 신약 허가 신청(NDA)에 대한 PDUFA 목표일을 2026년 4월 28일로 지정함. 신약 승인은 보통 5-10%의 주가 영향을 미칠 것으로 예상됨, 예정됨.
Related Recent Events
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release is scheduled for June 12, 2026, which is expected to have a high market impact (>=10%) as it provides the next official update on financial performance scheduled.
6/12/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Q4 and full-year fiscal 2026 earnings release scheduled.
5/20/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
The next quarterly earnings release on 2026-05-14 is scheduled.
5/14/2026, 12:00:00 AM
Roblox Corp (RBLX) · Earnings Release
Roblox's Q1 2026 earnings report is scheduled. Earnings releases typically cause significant price movement, but the immediate impact of the scheduling itself is estimated to be Low.
5/7/2026, 12:00:00 AM
Rockwell Automation Inc. (ROK) · Earnings Release
Medium importance is assigned as earnings releases typically result in significant price volatility; Q2 2026 earnings release is scheduled; analysts forecast EPS of approximately $2.88 estimated.
5/5/2026, 12:00:00 AM